secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apogee Therapeutics, Inc. (APGE)
CIK:        0001974640
Form:       8-K
Filed at:   2026-05-11T23:59:59+00:00
Accession:  0001193125-26-215683
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apogee reports Q1 loss of $74.1M; $1.3B cash; zumilokibart Phase 3 AD on track
------------------------------------------------------------------------------

- Net loss of $74.1M in Q1 2026 vs. $55.3M a year ago; R&D spend $60.8M, G&A $22.0M.
- Cash, equivalents and securities total $1.3B, up from $902.9M at Dec 2025, aided by $403M equity offering; runway into 2029.
- APEX Part A 52-week data: 75% (3-month) and 85% (6-month) of EASI-75 responders maintained; IGA 0/1 maintained at 86% and 78%.
- APEX Part B 16-week data in AD expected Q2 2026; Phase 3 AD initiation planned H2 2026.
- Positive Phase 1b asthma data shared Jan 2026; asthma and EoE trial details expected later this year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1974640/000119312526215683/0001193125-26-215683-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1974640/000119312526215683/apge-20260511.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-215683

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer